EU | pharmaphorum

EU

News

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Merck & Co's Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer therapy in the EU, ahead of Bristol-Myers Squibb's rival Opdivo, but BM

News

Libtayo gets a double with EU approvals in skin, lung cancer

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-

News

AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

The European Commission has approved AstraZeneca and MSD's Koselugo for a rare genetic condition that causes tumours to develop on the covering of nerve cells, leading to disfigurement and

News

After FDA rejection, EU says yes to Sanofi's Aubagio in kids...

Sanofi's Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple sclerosis in the EU, a few days after the same indication was turned

News

EU okays BMS' azacitidine pill for first-line maintenance of...

Bristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that has been mainstay of acute myeloid leukaemia (AML) therapy for more tha

News

EU and AZ both claim victory in COVID jab supply lawsuit

A court in Belgium has ordered AstraZeneca to deliver additional doses of its COVID-19 vaccine to EU member states by 27 September, although far fewer than the amount sought by the European

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Libtayo gets a double with EU approvals in skin, lung cancer

AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

After FDA rejection, EU says yes to Sanofi's Aubagio in kids...

EU okays BMS' azacitidine pill for first-line maintenance of...

EU and AZ both claim victory in COVID jab supply lawsuit

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

EU

Editor's Picks